Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohn's Disease | Biomarker Commons
Links shared publicly online about this topic.
- 61total visits
Quanterix Digital ELISA Measures Low Abundance Biomarkers of Inflammation in Crohn's Disease | Biomarker Commons
Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA) technology, today announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn's disease.
View full resource at biomarkercommons.org
Tags: IBD, Crohn's Disease, Disease and Condition, disease
Most Recently Shared on August 19, 2011 at 2:42 pm By:
Quanterix Digital ELISA Measures Low Abundance Biomarkers Of Inflammation In Crohn's Disease
medicalnewstoday.com — “Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced results of a pilot st” View full resource at medicalnewstoday.com
Most Recently Shared on August 20, 2011 at 7:05 am By:
Quanterix Digital ELISA Measures Low Abundance Biomarkers Of Inflammation In Crohn's Disease http://mnt.to/3Z5S #crohns #ibd
Advertisement
